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Since 24 states and the District of Columbia have legalized marijuana in some form,
suppliers of legal marijuana have developed Cannabis sativa products for use in
electronic cigarettes (e-cigarettes). Personal battery powered vaporizers, or e-cigarettes,
were developed to deliver a nicotine vapor such that smokers could simulate
smoking tobacco without the inherent pathology of inhaled tobacco smoke. The liquid
formulations used in these devices are comprised of an active ingredient such as
nicotine mixed with vegetable glycerin (VG) and/or propylene glycol (PG) and flavorings.
A significant active ingredient of C. sativa, cannabidiol (CBD), has been purported to
have anti-convulsant, anti-nociceptive, and anti-psychotic properties. These properties
have potential medical therapies such as intervention of addictive behaviors, treatments
for epilepsy, management of pain for cancer patients, and treatments for schizophrenia.
However, CBD extracted from C. sativa remains a DEA Schedule I drug since it has not
been approved by the FDA for medical purposes. Two commercially available e-cigarette
liquid formulations reported to contain 3.3 mg/mL of CBD as the active ingredient were
evaluated. These products are not regulated by the FDA in manufacturing or in labeling
of the products and were found to contain 6.5 and 7.6 mg/mL of CBD in VG and PG with
a variety of flavoring agents. Presently, while labeled as to content, the quality control of
manufacturers and the relative safety of these products is uncertain.
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INTRODUCTION
Electronic cigarettes (e-cigarettes) were developed as an alternative method for nicotine delivery.
Their utility and popularity have transformed them into a general drug-delivery device. They are
inexpensive, easy to use, and have some public perception as a healthy alternative. They work
by either drawing negative pressure through the mouthpiece or depressing a button to activate
a battery that heats a coil, containing a wick saturated with a formulation known as the e-liquid.
The e-liquids are made of some ratio of propylene glycol (PG) and vegetable glycerin (VG) and/or
a pharmaceutical and/or herbal remedy plus, potentially, a flavoring agent. When the e-cigarette
is activated, the e-liquid is vaporized, followed by rapid condensation into an aerosol that the user
inhales (Breland et al., 2016; Peace et al., 2016a).
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On May 5, 2016, the Food and Drug Administration (FDA)
announced the extension of their authority to regulate all
tobacco products, including e-cigarettes (U.S. Food and Drug
Administration [FDA], 2016). A significant reason to do so
was to address the quality assurance of e-cigarette products,
from the devices to the nicotine-based e-liquids contained
within. The e-liquid formulations have been found to vary
significantly from the labeled content around the world (Etter
et al., 2013; Goniewicz et al., 2013; Kavvalakis et al., 2015;
Pagano et al., 2015; Peace et al., 2016a). Since the legalization
of marijuana in some form in 24 states and the U.S. District of
Columbia, e-liquids containing cannabinoids have emerged in
the market place. As with nicotine e-liquid concentrations, the
measured concentration of19-tetrahydrocannabinol (THC) in a
commercially available product was found to contain significantly
different THC concentration than was labeled (Peace et al.,
2016b).
Cannabidiol (CBD) has been purported to have anti-
convulsant, anti-nociceptive, and anti-psychotic properties
(Brenneisen, 2007; Bhattacharyya et al., 2010). These properties
have potential medical therapies such as intervention of addictive
behaviors, treatments for epilepsy, management of pain for
cancer patients, and treatments for schizophrenia (Johnson
et al., 2010; Fischer et al., 2015; Friedman and Devinsky, 2015;
Manseau and Goff, 2015). According to the Drug Enforcement
Agency (DEA), CBD is a Schedule I substance as defined by
the Controlled Substances Act (CSA). Recently, the DEA made
it easier for scientists conducting FDA-approved studies to
acquire CBD (United States Drug Enforcement Administration
[DEA], 2016). Despite the ease of regulation for these research
purposes, the CSA still disallows the addition of CBD to products
for medicinal benefit since the FDA has not approved it for
medical intervention. In 2015 and 2016, the FDA issued warning
letters to companies marketing an unapproved drug in their
products for therapeutic benefit (United States Food and Drug
Administration [FDA], 2015a,b). Some companies selling
products containing CBD continue to claim medicinal value for
their products. However, some post the FDA disclaimer citing
that their products are “not intended for the diagnosis, cure,
mitigation, treatment, or prevention of a disease” according
to the Federal Food, Drug, and Cosmetic Act and that they
do not “distribute any products that are in violation of the
U.S. Controlled Substances Act (Cloud 9 Hemp, 2015; Isodiol,
2016).
Aside from volatile organic compounds and other potential
degradation products generated by an e-cigarette during
aerosolization which may pose health concerns (Flora et al.,
2016), condensation aerosols are known to be useful and
effective drug delivery systems. If research on CBD demonstrates
acceptable therapeutic utility and thereby removed from
Schedule I, the inhalation of CBD through an aerosol produced
by an e-cigarette may be advantageous over traditional smoking
methods and ingestion. THC enriched e-liquid vaporized in an
e-cigarette has been demonstrated to be an effective route of
administration for cannabinoids (Varlet et al., 2016). Of major
import is that these cannabinoid infused e-liquids be subjected to
manufacturing standards to ensure safety and quality of product.
Presented is the evaluation of two commercially available
e-liquids labeled to contain 3.3 mg/mL CBD in PG and VG
with flavorings. The vendor claims that a hemp strain with
the highest CBD potency was used in the manufacture of
their products (Cloud 9 Hemp, 2015). The products were
presumptively evaluated using Direct Analysis in Real Time ion
source attached to a time of flight mass spectrometer (DART-
MS) for cannabinoids, flavorants, and other possible constituents.
Cannabinoids were quantitated by high-performance liquid
chromatography–tandem mass spectrometry (HPLC-MS/MS).
Alcohols were analyzed by headspace gas chromatography with
flame ionization detector (HS-GC-FID). The aerosol produced
from the e-liquids with an e-cigarette was analyzed by solid phase
microextraction gas chromatograph (SPME-GC/MS).
MATERIALS
Two e-liquids, Cloud 9 Hemp Easy Rider and Yellow Brick
Road purported to be infused with CBD, were submitted to
the lab for analysis. These products contained no information
as to lot number or date of production (Figure 1). All tubing,
glassware, and fritted gas dispersion tubes were purchased
from Colonial Scientific (Richmond, VA, USA). HPLC-grade
methanol used for all dilutions, stock and working solutions
was purchased from Pharmco-Aaper (Brookfield, CT, USA).
Polyethylene glycol (PEG) with an average molecular mass
of 600 Da was used for DART-MS calibration and obtained
from ULTRA Inc (North Kingstown, RI, USA). United States
Pharmacopiea (USP)-grade PG and VG were obtained from
Wizard Labs (Altamonte Springs, FL, USA). Nitrogen and helium
gases were acquired from Praxair and Airgas (Richmond, VA,
USA). Certified ACS Ammonium acetate, formic acid, HPLC-
grade methanol and de-ionized (DI) water, optima grade acetone,
ethanol, methanol, n-propanol, and isopropanol were purchased
from Fisher Scientific (Hanover Park, IL, USA). Medical-grade
nitrogen and helium were purchased from National Welders
Supply Company (Richmond, VA, USA). CBD primary reference
standard was purchased from Cerilliant (Round Rock, TX, USA).
The e-cigarette was a KangerTech Aerotank clearomizer (v2)
attached to an eGo-V v2 variable voltage battery, purchased from
101vape.com (Carlsbad, CA, USA). The single coil was wrapped
in non-contact configuration with 34 gauge Nichrome wire to
1.8  and a 2 mm diameter silica string was used as a wick. The
flow meter was purchased from Cole Palmer (Vernon Hills, IL,
USA). Seven micrometers polydimethylsiloxane (PDMS) SPME
fibers were purchased from Supelco (Bellefonte, PA, USA).
METHODS
Screening of Cannabidiol E-Liquids by
DART-MS
A previously published method employing a JEOL JMS T100LC
Accu-TOF mass spectrometry controlled by Mass Center
software version 1.3.4 m (JEOL Inc., Tokyo, Japan) was used
to screen both CBD infused e-liquids for the presence of
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FIGURE 1 | (A) Easy Rider and Yellow Brick Road CBD e-liquids with (B) the FDA statement regarding the uses of the e-liquid, and (C) the listed ingredients of the
e-liquids.
cannabinoids, flavoring agents, and other possible components
(Poklis et al., 2015a,b). Briefly, a capillary tube was dipped five
times into an aliquot of each e-liquid prior to introduction into
the helium stream of a DART-MS. Each sample was analyzed in
positive-ion mode with a helium stream temperature of 300◦C.
The flow rate was 2.3 L/min with a discharge electrode needle
voltage at 150 V and grid electrode at 250 V. The ion guide
peak voltage was 400 V, reflectron voltage was 900 V, orifice 2
was set to 5 V, and the ring lens was set to 3 V with orifice 1
operated in function switching mode at 20, 60, or 90 V with a
single data file created for all three voltages. The range of masses
measured was from 40 to 1,100 Da. Each e-liquid was analyzed
five separate times to ensure reproducibility of the results. The
data was analyzed by the creation of averaged, background
subtracted, centroided mass spectra that was calibrated using the
PEG 600. Identification of CBD was made when the exact mass
was detected within 5 mDa of its calculated monoisotopic mass
(M+H)+ and by its fragmentation pattern in function switching
mode. PG and VG were confirmed by known standard analysis.
All other compounds detected in the e-liquid were identified
using a NIST 11.0 library.
Volatile Analysis of Cannabidiol
E-Liquids Headspace GC-FID
A validated analytical method routinely used for the analysis
of clinical and forensic samples for ethanol, acetone,
isopropanol, and methanol was employed using a Tekmar
HT3 headspace sampler attached to a Shimadzu 2014 GC-FID.
The chromatographic separation was performed on a RTX-BAC1
(30 m× 0.32 mm id× 1.80 µM column (Restek Corp, Bellefonte,
PA, USA). The headspace oven and transfer line temperatures
were set to 160◦C with a standby flow rate of 200 mL/min. The
platen sample temperature was 80◦C with the mixer on. The
sample equilibrium time was 3.5 min with a sample injection
time of 0.5 min. The GC has an oven temperature of 50◦C and
the injection temperature of 200◦C run in split mode with a
1:20 ratio. The column flow rate was 6.85 mL/min with purge
flow of 0.5 mL/min, and the detector temperature was 225◦C.
Calibrators, controls and the CBD e-liquids were diluted with
the internal standard, 234 mg/L n-propanol in water, at 1:10 ratio
prior to analysis. The limit of detection (LOD) for all volatiles
was 100 mg/L with a determined linear range of 100–8,000 mg/L
for the assay.
Quantification of Cannabidiol E-Liquids
by HPLC-MS/MS
Quantification of CBD was performed using a modification of a
previously validated method (Poklis et al., 2010) on an Applied
Biosystems 3200 Q Trap with a turbo V source for TurboionSpray
(Applied Biosystems, Foster City, CA, USA) tandem mass
spectrometer (MS/MS) attached to a Shimadzu SCL HPLC
system (Shimadzu Corp., Kyoto, Japan) with a Zorbax eclipse
XDBC18 column 4.6 mm× 75 mm, 3.5 µ (Agilent Technologies,
Santa Clara, CA, USA) controlled by Analyst 1.4.2 software. The
mass spectrometer detector was operated in scan mode with a
mass range of 50–700 Da. The injection volume was 10 µL. The
mobile phase was 10:90 (v:v) methanol:DI water with a pump
flow rate of 0.5 mL/min. The ion spray voltage was 5,000 V
with ion source gases 1 and 2 having flow rates of 60 mL/min.
The source temperature was set at 650◦C and the curtain gas
flow rate was 30 mL/min. The following transition ions (m/z)
were monitored with their corresponding collection energies of
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29 eV: CBD: 315 > 193, 315 > 259 and CBD-d3: 318 > 196,
318 > 261. The total run time was 8.0 min. Each e-liquid was
diluted 1:10,000 and 1:100,000 with methanol. A CBD calibration
curve was prepared in duplicate with a range of 10–100 ng/mL.
Quality controls specimens of 10, 30, 300, and 750 ng/mL of
CBD were prepared in triplicate. A linear regression of the ratio
of the peak area counts of cannabinoids and the deuterated
internal standards versus concentration was used to construct
the calibration curves with a coefficient of determination (r2) of
0.9995. The transition ions’ relative abundances for the identified
cannabinoids were ±20% of target, relative to the calibrators.
All quality control specimens were within 15% of their expected
target values.
Analysis of the Aerosol Generated by
Cannabidiol E-Liquids
The CBD e-liquids were mixed by hand for 20 s before adding
them to a clean KangerTech e-cigarette. The aerosol produced
by the e-cigarette was trapped with common glassware. Briefly,
two Erlenmeyer flasks were connected in tandem to a vacuum
with a flow rate of 2.3 L/min. DI water was added to each trap
and a gas dispersion tube bubbled the aerosol into the water.
Glass wool was placed in between the two traps to contain the
aerosol in the first trap. A 7 µm PDMS SPME fiber was inserted
through a stopper in the first trap. The fiber was introduced into
the trap while the e-cigarette was activated and the aerosol filled
the trap. The e-cigarette was activated for 4 s, aerosolizing 7–
10 µL of the e-liquid, and the SPME fiber was held in the trap for
5 min, after which the fiber was retracted. The SPME fiber was
inserted into the injection port of an Agilent GC-MS 6890N/5973
Mass Selective Detector (Agilent, Santa Clara, CA, USA) with
an HP-5MS column 30 m × 0.25 mm id × 0.25 µm (Agilent,
Santa Clara, CA, USA). The injection port was set to 315◦C
and the run was made in splitless mode with a 15 min thermal
desorption time. The initial temperature was set to 120◦C, with
a ramp of 300◦C at 10◦C/min, and then a hold time of 12 min,
for a total run time of 30 min. Five separate samplings were
collected for each e-liquid. The fibers were thermally cleaned
between runs following manufacturer specifications to ensure
no carryover occurred between samples. A 100 ng/mL CBD
reference standard was also analyzed on the GC-MS and the
combination of retention time and mass spectrum were used to
identify CBD in the aerosolized e-liquids. Flavoring agents were
identified using a NIST 11.0 library.
RESULTS
Cloud 9 Hemp Yellow Brick Road and Easy Rider e-liquids
were determined to contain 7.6 and 6.5 mg/L CBD, respectively.
Both e-liquids were found to contain PG and VG (65:35
v:v). Yellow Brick Road and Easy Rider e-liquids were
also determined to contain 3,600 and 6,600 mg/L ethanol,
respectively. Yellow Brick Road was determined to contain
the following flavoring agents: peach lactone, y-decalactone,
and vanillin, and Easy Rider contained ethyl maltol, ethyl
vanillin, vanillin, y-nonalactone, benzaldehyde PG acetal,
dimethyl anthranilate, propenylguaethol, 6-methylcoumarin,
and heliotropin PG acetal (Table 1). The analysis of the aerosol
generated using Yellow Brick Road and Easy Rider e-liquids
in the KangerTech e-cigarette resulted in the detection of the
CBD, PG, VG, and flavoring agents found in the e-liquids
(Supplementary Figure S1).
DISCUSSION
Electronic cigarettes have become a popular means for using
pharmaceuticals other than nicotine. This study characterized
commercially available e-liquids that were advertised as
containing CBD. DART-MS was used to assess the presence of
PG, VG, CBD, and a flavor profile for each of the e-liquids. It
was also used to evaluate the e-liquids for any other potential
constituents. Volatile analysis was used to detect and quantitate
the presence of ethanol within the samples. The CBD detected
using the DART-MS method was then quantitated using HPLC-
MS/MS, and SPME-GC/MS was used to identify compounds
aerosolized by the e-cigarette. Only a single cannabinoid,
CBD, was detected by the DART-MS, HPLC-MS/MS, and
SPME-GC/MS methods.
SPME has historically been used in order to characterize
the smoke of traditional cigarettes (Watson et al., 2004). One
such study, performed by Bao et al. (2010), used HS-SPME to
determine the concentration of free-base nicotine in cigarette
TABLE 1 | Compounds detected in the Easy Rider and Yellow Brick Road
e-liquids by DART-MS and SPME-GC/MS analysis.
Compound Formula Monoisotopic
MW (g/mol)
DART-MS
[M+H]+
SPME-
GC/MS RT
(minute)
Easy Rider
Ethyl maltol C7H8O3 140.047 141.061 3:07
Benzaldehyde
propylene glycol acetal
C10H12O2 164.084 ND 3:45
Wine ether C11H22O2 186.162 187.174 3:44
γ-Nonalactone C9H16O2 156.115 157.123 4:28
Vanillin C8H8O3 152.047 153.060 4:50
Dimethyl anthranilate C9H11NO2 165.079 166.091 4.95
Ethyl vanillin C9H10O3 166.063 ND 5:24
Propenylguaethol C11H14O2 178.099 179.112 6:05
6-Methylcoumarin C10H8O2 160.052 161.069∗ 6:34
Heliotropin propylene
glycol acetal
C11H12O4 208.074 209.074 7:14
Benzyl benzeneacetate C15H14O2 226.099 ND 9:06
Cannabidiol C21H30O2 314.225 315.232 14:39
Yellow Brick Road
Isomenthol acetate C12H22O2 198.162 ND 3.82
Vanillin C8H8O3 152.047 153.062 4:50
Peach lactone C11H20O2 184.146 185.151 5:29
γ-Decalactone C10H18O2 170.131 171.141 6:35
Cannabidiol C21H30O2 314.225 315.232 14:39
MW, molecular weight; ND, not detected by DART-MS.
∗Confirmation by GC-MS. Low abundance in DART-MS prohibited identification.
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smoke. Another study performed by Ye (2008) used SPME-
GC/MS in order to analyze any volatile organic compounds
found from cigarette smoke from 10 different types of traditional
cigarettes. Wu et al. (2002) were also capable of detecting
the abundant alkaloids from cigarette smoke from 14 different
countries. The present study sought to use a similar concept in
order to analyze condensation aerosol of e-liquids containing
CBD in order to characterize the aerosol produced by the
e-liquids. The e-cigarette aerosolized the CBD as it was
successfully extracted from the aerosol using SPME, then
thermally desorbed by GC/MS. The final chromatographic profile
of the aerosol included PG, VG, CBD, and flavoring agents. No
carbonyl compounds were detected in the aerosol produced by
the e-liquid using the SPME-GC/MS method presented. These
compound have been detected by other investigators in aerosols
by other methodologies (Bekki et al., 2014; Kosmider et al., 2014;
Flora et al., 2016; Jensen et al., 2015).
While there is no current literature regarding trends among
the quality control of CBD containing e-liquids, there have
been several involving quantitative studies of nicotine-based
e-liquids. Two studies by Goniewicz et al. (2013, 2014) involved
the analysis of the concentration of nicotine in cartridges and
e-liquids from the UK, Poland, and the United States while
Kavvalakis et al. (2015) evaluated products available on the Greek
market. Etter et al. (2013), Lisko et al. (2015), and Trehy et al.
(2011) analyzed e-liquids and cartridges for flavoring agents,
nicotine, and potential nicotine impurities. Pagano et al. (2015)
evaluated products purchased in the United States, as did this
research group (Peace et al., 2016a). These studies all noted
that there was a difference in quantity from the advertised
concentration of the active pharmaceutical from the actual
concentration, some to be significant. The previous study by
Peace et al. (2016b) found that 30% of the e-liquids purchased
in the United States had greater than a 20% difference from the
labeled concentration of nicotine. This research group also found
that a commercially available product, labeled as 69.1% THC
and 1.0% CBD, actually contained 42.6% THC (w/v) and 0.5%
CBD (w/v). They also found that the THC e-liquid contained
four additional cannabinoids and 13 terpenes, indicating that the
product was created by extracting Cannabis sativa (Peace et al.,
2016b). The CBD e-liquids evaluated in this study both contained
over twice the advertised concentrations of CBD and also ethanol.
Since the e-liquids in this study did not contain any terpenes nor
were there any other cannabinoids detected, it could be deduced
that the CBD was not produced by an extraction of marijuana.
The detection of the unlabeled ethanol in these products may
have been used as a natural flavorant or as a solvent, however,
the reason for the ethanol as an ingredient cannot be fully
ascertained. The flavorants detected by DART-MS and/or SPME-
GC/MS were only included on the product labels as “Natural and
Artificial Flavorings.” Lack of regulation provides opportunities
for products to be developed without the oversight for the
quantity, quality, and safety of products. While they may not
necessarily be harmful to the user, it could be important for a
consumer, who is trying to monitor their CBD use for medical
intervention, to know.
CONCLUSION
The e-liquids analyzed in this study both screened positive
for CBD by DART-MS and were confirmed to have CBD
present by HPLC-MS/MS. SPME was effective in extracting CBD
and the other components produced by e-cigarette to confirm
aerosolization. The contents of the e-liquids were labeled to
contain 3.3 mg/mL of CBD. They were found to contain 6.5 and
7.6 mg/mL of CBD. The analysis of these two different products
illustrates the potential quality control issues that can occur in an
unregulated industry. Even with uncertain safety of e-cigarettes
and e-liquids, the e-cigarette used was shown to generate
an aerosol containing CBD using the commercially available
e-liquids. Vaping CBD would eliminate harmful combustion
products of smoking, while still employing the advantages of
inhalation over ingestion. As research continues to understand
the effects of CBD and its potential therapeutic properties
the e-cigarettes many prove a useful CBD drug delivery
system.
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